Risk of hepatitis B virus reactivation in hepatitis B virus?+?hepatitis C virus‐co‐infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r?+?dasabuvir?+?ribavirin

导出原文传递

翻译打印收藏纠错

作者： Preda C. M. ^[1] ; Popescu C. P. ^[2] ; Baicus C. ^[3] ; Constantinescu I. ^[4] ; Oproiu A. ^[5] ; Voiosu T. ^[6] ; Diculescu M. ; Negreanu L. ; Gheorghe L. ; Sporea I. ; Trifan A. ; Ceausu E. ; Proca D. ; Manuc M.

作者单位： UMF Timisoara, Gastroenterology & Hepatology DepartmentTimisoara Emergency HospitalTimisoara,Romania ^[1] UMF Gr T Popa Iasi, Gastroenterology & Hepatology DepartmentGastroenterology & Hepatology ^[2] UMF “Carol Davila” Gastroenterology DepartmentEmergency Universitary HospitalBucharest,Romania ^[3] UMF “Carol Davila” Gastroenterology & Hepatology DepartmentClinic Fundeni InstituteBucharest,Romania ^[4] UMF “Carol Davila” Virology DepartmentVictor Babes HospitalBucharest,Romania ^[5] UMF “Carol Davila” Internal Medicine DepartmentColentina HospitalBucharest,Romania ^[6]

关键词 direct‐acting antiviral agents HBV reactivation hepatitis B virus hepatitis C virus liver cirrhosis paritaprevir/ombitasvir/ritonavir/dasabuvir?+?ribavirin

发布时间 2020-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交